P
BMRN icon

Pitcairn’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pitcairn’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,658
Closed -$204K – 518
2020
Q2 		$204K Buy
+1,658
New +$165K 0.02% 464
2019
Q4 		– Sell
-3,629
Closed -$244K – 546
2019
Q3 		$244K Sell
3,629
-442
-11% -$34K 0.02% 462
2019
Q2 		$349K Sell
4,071
-171
-4% -$14.6K 0.03% 337
2019
Q1 		$376K Sell
4,242
-168
-4% -$15.6K 0.04% 279
2018
Q4 		$375K Sell
4,410
-115
-3% -$10.9K 0.04% 241
2018
Q3 		$439K Sell
4,525
-347
-7% -$34.6K 0.05% 287
2018
Q2 		$459K Sell
4,872
-44
-0.9% -$3.85K 0.05% 270
2018
Q1 		$398K Sell
4,916
-208
-4% -$17.9K 0.04% 290
2017
Q4 		$457K Sell
5,124
-194
-4% -$16.9K 0.05% 281
2017
Q3 		$495K Sell
5,318
-586
-10% -$51.8K 0.06% 249
2017
Q2 		$536K Sell
5,904
-74
-1% -$6.73K 0.06% 225
2017
Q1 		$524K Sell
5,978
-684
-10% -$60.9K 0.06% 239
2016
Q4 		$552K Sell
6,662
-845
-11% -$72.7K 0.07% 219
2016
Q3 		$695K Sell
7,507
-284
-4% -$26.7K 0.09% 180
2016
Q2 		$607K Buy
7,791
+734
+10% +$62.4K 0.08% 191
2016
Q1 		$582K Buy
7,057
+440
+7% +$35.8K 0.07% 206
2015
Q4 		$693K Sell
6,617
-233
-3% -$24.3K 0.08% 188
2015
Q3 		$722K Buy
6,850
+668
+11% +$89.2K 0.1% 177
2015
Q2 		$846K Sell
6,182
-32
-0.5% -$3.97K 0.1% 173
2015
Q1 		$774K Sell
6,214
-931
-13% -$98.6K 0.09% 184
2014
Q4 		$646K Buy
7,145
+169
+2% +$14.1K 0.07% 202
2014
Q3 		$504K Sell
6,976
-7,643
-52% -$502K 0.06% 254
2014
Q2 		$910K Buy
14,619
+8,381
+134% +$506K 0.1% 163
2014
Q1 		$426K Sell
6,238
-280
-4% -$20.6K 0.05% 278
2013
Q4 		$459K Sell
6,518
-1,188
-15% -$80.7K 0.05% 278
2013
Q3 		$556K Buy
7,706
+280
+4% +$18.6K 0.07% 222
2013
Q2 		$414K Buy
+7,426
New +$463K 0.06% 276

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Pitcairn's BMRN Position: Q3 2020 in Review

Pitcairn sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 1,658 shares — an estimated $204K sold.

Pitcairn first reported a position in BMRN in Q2 2013 and held it in 27 quarters. The position peaked at $910K in Q2 2014. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

  • Pitcairn reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Pitcairn sold 1,658 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $204K.
  • Pitcairn first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • Pitcairn's BioMarin Pharmaceuticals position peaked at $910K in Q2 2014.
  • 496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Pitcairn's 13F filing for Q3 2020, filed 3 Nov 2020.